Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
LewisDaKat
LewisDaKat Jul. 15 at 5:00 PM
$RHHBY FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy https://marketwirenews.com/stock/rhhby/news/fda-grants-priority-review-to-genentech-s-gazyva-for-4598827254172937.html?utm_source=stocktwits
0 · Reply
GoforProMIS
GoforProMIS Jul. 15 at 1:50 PM
$PMN The status of potential takeover talks is standard practice in the biotech industry for a company like ProMIS to engage in intensive business development following such data—meaning, for instance, holding direct discussions with representatives from $BIIB , $LLY , $RHHBY at the AAIC conference in London IMO let’s see what happens https://www.promisneurosciences.com/investors/news-events/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of
0 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:52 PM
$RHHBY $AMGN $AZN While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience Ticker: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 10 at 4:25 PM
1. Good luck on #PDUFA 7/29/26 #OutlookTherapeutics! #OTLK $OTLK not mentioned in article. #wetAMD #eyes #opthalmology #pharma #potential #blockbuster #bevacizumab 2. $BAYRY $RHHBY Is there a name for something structured like that event in the article-example so much up front, AND some at different milestones? Maybe it’s called Contingent Considerate Acquisition, or maybe contingent earn outs? https://www.fiercepharma.com/pharma/bayers-eylea-declines-24-bearing-brunt-biosmilar-competition. 3. Is it typical for milestones category to be a greater number than upfront with contingent considerate acquisitions?
0 · Reply
scotttrader213
scotttrader213 Jul. 10 at 1:01 AM
$RHHBY An amazing pipeline, that seems to be moving in the right direction, but can’t move above 60! The revenue, the distribution, and a well run management.. I gather the street not on board!
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 6:46 PM
$RHHBY Current Stock Price: $52.18
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 4:38 AM
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY $SLS $ABBV $RHHBY $BMY https://stocktwits.com/news/equity/markets/sls-aml-trial-big-pharma-abbv-rhhby-bmy-drug-combo/cZmomx9R7Vl
0 · Reply
Bobear12
Bobear12 Jul. 7 at 7:25 PM
$RHHBY why doesn’t LLY buy GALt before Novartis or Roche does? Bo-ask
0 · Reply
GoforProMIS
GoforProMIS Jul. 7 at 3:26 PM
Full Alzheimer Disease Analyze: If $PMN can use its blinded data to demonstrate that it can achieve the same therapeutic effect as Leqembi or Kisunla without the associated side effects, the stock is poised for extremely dynamic catch-up growth relative to these multi-billion-dollar corporations. $BIIB Drug: Leqembi®️ (lecanemab) FDA-approved. Issue: Slows cognitive decline by approximately 27% but carries the well-known, high ARIA safety risk (approx. 13% incidence of brain swelling in studies). $LLY Kisunla FDA-approved. Issue: Slows decline by up to 35% but has the highest ARIA rate on the market due to its biological mechanism. Phase 3 drugs: $RHHBY Trontinemab Status is a highly sophisticated antibody utilizing "brain shuttle" technology. $AXSM Auvelity FDA expanded approval to include the treatment of agitation associated with AD. $ AVXL Blarcamesine Phase 3 completed. Not an antibody, but an oral tablet. A completely different biological pathway compared to $PMN!
0 · Reply
Bobear12
Bobear12 Jul. 6 at 3:20 PM
$RHHBY Red vs Green Rhhby and GALT running neck to neck today. Which will finish first? Bo-nos
0 · Reply
Latest News on RHHBY
No data available.
LewisDaKat
LewisDaKat Jul. 15 at 5:00 PM
$RHHBY FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy https://marketwirenews.com/stock/rhhby/news/fda-grants-priority-review-to-genentech-s-gazyva-for-4598827254172937.html?utm_source=stocktwits
0 · Reply
GoforProMIS
GoforProMIS Jul. 15 at 1:50 PM
$PMN The status of potential takeover talks is standard practice in the biotech industry for a company like ProMIS to engage in intensive business development following such data—meaning, for instance, holding direct discussions with representatives from $BIIB , $LLY , $RHHBY at the AAIC conference in London IMO let’s see what happens https://www.promisneurosciences.com/investors/news-events/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of
0 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:52 PM
$RHHBY $AMGN $AZN While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience Ticker: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 10 at 4:25 PM
1. Good luck on #PDUFA 7/29/26 #OutlookTherapeutics! #OTLK $OTLK not mentioned in article. #wetAMD #eyes #opthalmology #pharma #potential #blockbuster #bevacizumab 2. $BAYRY $RHHBY Is there a name for something structured like that event in the article-example so much up front, AND some at different milestones? Maybe it’s called Contingent Considerate Acquisition, or maybe contingent earn outs? https://www.fiercepharma.com/pharma/bayers-eylea-declines-24-bearing-brunt-biosmilar-competition. 3. Is it typical for milestones category to be a greater number than upfront with contingent considerate acquisitions?
0 · Reply
scotttrader213
scotttrader213 Jul. 10 at 1:01 AM
$RHHBY An amazing pipeline, that seems to be moving in the right direction, but can’t move above 60! The revenue, the distribution, and a well run management.. I gather the street not on board!
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 6:46 PM
$RHHBY Current Stock Price: $52.18
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 4:38 AM
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY $SLS $ABBV $RHHBY $BMY https://stocktwits.com/news/equity/markets/sls-aml-trial-big-pharma-abbv-rhhby-bmy-drug-combo/cZmomx9R7Vl
0 · Reply
Bobear12
Bobear12 Jul. 7 at 7:25 PM
$RHHBY why doesn’t LLY buy GALt before Novartis or Roche does? Bo-ask
0 · Reply
GoforProMIS
GoforProMIS Jul. 7 at 3:26 PM
Full Alzheimer Disease Analyze: If $PMN can use its blinded data to demonstrate that it can achieve the same therapeutic effect as Leqembi or Kisunla without the associated side effects, the stock is poised for extremely dynamic catch-up growth relative to these multi-billion-dollar corporations. $BIIB Drug: Leqembi®️ (lecanemab) FDA-approved. Issue: Slows cognitive decline by approximately 27% but carries the well-known, high ARIA safety risk (approx. 13% incidence of brain swelling in studies). $LLY Kisunla FDA-approved. Issue: Slows decline by up to 35% but has the highest ARIA rate on the market due to its biological mechanism. Phase 3 drugs: $RHHBY Trontinemab Status is a highly sophisticated antibody utilizing "brain shuttle" technology. $AXSM Auvelity FDA expanded approval to include the treatment of agitation associated with AD. $ AVXL Blarcamesine Phase 3 completed. Not an antibody, but an oral tablet. A completely different biological pathway compared to $PMN!
0 · Reply
Bobear12
Bobear12 Jul. 6 at 3:20 PM
$RHHBY Red vs Green Rhhby and GALT running neck to neck today. Which will finish first? Bo-nos
0 · Reply
Jumpman23
Jumpman23 Jul. 2 at 8:03 PM
$RHHBY waking up
0 · Reply
Stockswingalert
Stockswingalert Jun. 29 at 6:32 PM
$CLPT if you late here to the 💎 party 🔐 sponsored by #lockedintrading @Stockswingalert LLC My good exclusive karma and way to pay it forward for my OG crowd on here cc @Stocktwits 🙏🎯👇💰 for ONLY free.99 🤝🤝🤝 Is to watch the gap fill here at $19.68 ☢️📈 In a world selling gold (gene therapy), sometimes the better bet is to buy the shovels… In this case that is this right here 👇👇👇 cc $QURE $CRSP $RHHBY #roche
0 · Reply
TickrTalk0007
TickrTalk0007 Jun. 29 at 2:28 PM
$NVDA yes...please take this to OTC and remove options trading.... then see what happens... $RHHBY is the largest pharma and trades on OTC
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 28 at 12:59 AM
$SLS With the 80th Event Now Truly Imminent, after 5 years - the Share Price / Market Action Sure is doing what you would expect -if- the people* who really understand the drug space are confident in Gps Success. * $ABBV $RHHBY who own the Azacitidine Venetoclax - BAT for Control Arm Patients * Fund Analysts Buying the Share Price Up - Paying Attention to every Last Scrap of Published Trial Data and any information relative and pertinent - etc., etc., etc. ie BAT Failing 3 AML Remission Maintenance Trials - Gps Proven Effective in 2 Phase 2 AML Remission Maintenance trials w 2x and 4x+ Statistically Significant Results - IDMC UNBLINDING ACTUAL Phase 3 MOS and Immune Response Data - 80% IR in the P3 / vs 64% in the P2 - IR is Dir Correlated w Survival. Smarter Money than US Knows.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 7:12 PM
$SLS $ABBV $RHHBY - 47 days Since the 78th Event PR - 22 Days Per EVENT Rate. 80th Event and Ensuing Share Price LAUNCH is Now Truly imminent.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 26 at 3:57 PM
$SLS Gps Treatment ARM MOS is now > 31.5 Months BAT / Aza+VEN $ABBV $RHHBY Failed 3 AML Remission maintenance Trials. VIALE-M CR1 Remission Maintenance Phase 3 Trial Failed VIALE-T Post Transplant Maintenance Phase 3 Trial Failed - Last week PH2/ low dose, all Oral combo - FAILED This $12 Stock is going to be a $100 Stock and More. Mark this Post. Smart Money Knows. ​$ABBV up $25B in Market Value Last 2 Days...
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Jun. 25 at 5:59 PM
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Why the Stock Impact May Be More Limited Than It Looks: https://www.fool.com/investing/2026/06/23/jazz-pharmaceuticals-lung-cancer-drug-setback-in-l/ $JAZZ $RHHBY
0 · Reply
biotech
biotech Jun. 25 at 4:24 PM
$SGMO $SGMO The Bidding War: $LLY vs. Genentech/ $RHHBY Roche If $BIIB data in July proves that stopping tau is the holy grail for curing Alzheimer's these giant companies will look at Sangamo’s safe permanent "Zinc Finger" switch and realize they need to buy it ad then STAC-BBB
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 24 at 7:12 PM
$SLS SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. - the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th. That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials - Prevent Relapse and Extend Survival - Directly Correlated with Immune Response- SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events.. - penny flipping idiots are going regret for the rest of their Miserable Short Lives, for selling for anything less than $100 Per Share - now you know.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 24 at 6:31 PM
$SLS IDMC UNBLINDED ACTUAL MOS AND IR DATA FROM THIS ONGOING P3 INTERIM ANALYSIS - Only inch thick tools don’t get it Now 47 Days since the 78th Event 72nd Dec 26th - 78th May 11 --- 6 Events in 136 Days / Approximately 1 Event Every 22 Days - > Monday was the Bullseye 4 the 80th Event PR. - and the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th. That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials - Prevent Relapse and Extend Survival - Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events.. penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $100 Per Share - now you know. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
DidYouReadThis
DidYouReadThis Jun. 23 at 8:31 PM
DD super readers, what companies to you predict to be a potential buy out target by 2030 whether by $PFE, $RHHBY $ABBV $LLY or a different co?
0 · Reply
scotttrader213
scotttrader213 Jun. 23 at 11:59 AM
$RHHBY major disappointment for 2026.
0 · Reply